IMMUNPROTEASOMINHIBITOREN

Patent europeic · EP3710457 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3710457
Numer da la dumonda
EP18812554
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
14-11-2018
Publitgà
23-09-2020
Concedì
03-08-2022
La protecziun finescha il pli tard
13-11-2038
Proxima taxa annuala scadenta
30-11-2026
Classas IPC
C07F 5/04 (2006.01)
A61P 9/00 (2006.01)
A61K 31/69 (2006.01)
Prioritad
US 201762587375 P 16.11.2017
Dumonda PCT
PCT/US2018/061132 14.11.2018
Publicaziun PCT
WO2019/099576 23.05.2019
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-12-2025

    Midada

    Published in Swissreg on 01.12.2025

  2. 01-12-2024

    Midada

    Published in Swissreg on 01.12.2024

  3. 01-12-2023

    Midada

    Published in Swissreg on 01.12.2023

  4. 14-06-2023

    Midada

    Published in Swissreg on 14.06.2023

  5. 01-12-2022

    Midada

    Published in Swissreg on 01.12.2022

  6. 03-08-2022

    Concedì

    Published in Swissreg on 03.08.2022

Partidas

Possessur

Principia Biopharma Inc.

220 East Grand Avenue, South San Francisco, CA 94080, US

Inventur

LOU, Yan

South San Francisco, CA 94080, US

BRAMELD, Kenneth Albert

South San Francisco, CA 94080, US

OWENS, Timothy Duncan

South San Francisco, CA 94080, US

GOLDSTEIN, David Michael

South San Francisco, CA 94080, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.